Yduqs Participações (YDUQ3) investor relations material

Executive summary

• Achieved solid operational and financial results in Q2 2026, with all business units contributing to growth and profitability, led by premium courses and strong student renewal rates.

• IDOMED and Ibmec posted record student intake and robust EBITDA growth, reinforcing leadership in medical and premium education segments.

• Continued focus on cash generation, disciplined capital allocation, and shareholder returns, with R$780 million returned since 2024.

• Recognized for ESG initiatives, including international awards and increased female representation in senior management.

• Completed significant corporate restructuring and acquisitions, expanding presence and operational scale.

Financial highlights

• Consolidated net revenue for 1H26 reached BRL 2,900.9 million, up 1.2% year-over-year; adjusted for DIS, NOR grew 4.1%.

• Adjusted EBITDA was R$904.2M in 1H26, stable year-over-year, with margin at 31.2%; IDOMED's EBITDA margin reached 48%.

• Adjusted net income was R$164.1M in 1H26, down 11% year-over-year, mainly due to lower DIS participation and higher Selic rate.

• Bad debt as a percentage of NOR improved by 1.5 p.p. year-over-year, reaching 11% in 1H26.

• R$780M returned to shareholders since 2024 via dividends and buybacks, representing 37% of market cap.

Outlook and guidance

• Positive outlook for 2H26, supported by expected normalization of DIS impacts, lower Selic rates, and operational improvements.

• Guidance reaffirmed for FCFE earnings per share between BRL 1.4 and BRL 2, and total FCFE of BRL 520–620 million.

• Targeting net debt/EBITDA of 1.0x by end of 2027, with leverage at 1.55x in Q2 2026.

• No major debt maturities until 2027; focus on extending and reducing debt cost.

• Transitioning to a new tax regime due to Brazil's tax reform, with no expected impact on 2026 results.